- Home
- RPTX vs XFOR Comparison
RPTX vs XFOR Comparison
Compare RPTX & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- XFOR
- Stock Information
- Founded
- RPTX 2016
- XFOR 2014
- Country
- RPTX Canada
- XFOR United States
- Employees
- RPTX N/A
- XFOR N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPTX Health Care
- XFOR Health Care
- Exchange
- RPTX Nasdaq
- XFOR Nasdaq
- Market Cap
- RPTX 119.7M
- XFOR 118.4M
- IPO Year
- RPTX 2020
- XFOR N/A
- Fundamental
- Price
- RPTX $3.75
- XFOR $0.62
- Analyst Decision
- RPTX Strong Buy
- XFOR Buy
- Analyst Count
- RPTX 3
- XFOR 3
- Target Price
- RPTX $17.33
- XFOR $3.67
- AVG Volume (30 Days)
- RPTX 151.6K
- XFOR 738.6K
- Earning Date
- RPTX 11-07-2024
- XFOR 11-07-2024
- Dividend Yield
- RPTX N/A
- XFOR N/A
- EPS Growth
- RPTX N/A
- XFOR N/A
- EPS
- RPTX N/A
- XFOR 0.09
- Revenue
- RPTX $68,683,000.00
- XFOR $563,000.00
- Revenue This Year
- RPTX $16.85
- XFOR N/A
- Revenue Next Year
- RPTX N/A
- XFOR $596.79
- P/E Ratio
- RPTX N/A
- XFOR $7.20
- Revenue Growth
- RPTX N/A
- XFOR N/A
- 52 Week Low
- RPTX $2.71
- XFOR $0.53
- 52 Week High
- RPTX $8.49
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- RPTX 68.01
- XFOR 40.30
- Support Level
- RPTX $3.37
- XFOR $0.60
- Resistance Level
- RPTX $3.72
- XFOR $0.65
- Average True Range (ATR)
- RPTX 0.19
- XFOR 0.04
- MACD
- RPTX 0.03
- XFOR -0.01
- Stochastic Oscillator
- RPTX 85.60
- XFOR 13.65
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.